Maastricht University is a public university in Maastricht, the Netherlands. Founded in 1976, the university is the second youngest of the 13 Dutch universities.In 2013, nearly 16,000 students studied at Maastricht University, 47% of whom were foreign students, with over 3,200 employees employed. About half of the bachelor's programmes are fully offered in English, while the other half is taught wholly or partly in Dutch. Most of the master's and doctoral programmes are in English. In 2013, Maastricht University was the second Dutch university to be rewarded the ‘Distinctive Quality Feature for Internationalisation’ by the Accreditation Organisation of the Netherlands and Flanders .Besides traditional programmes, Maastricht University also has an honours liberal arts college: University College Maastricht and a Maastricht Science Programme in the same liberal arts tradition. Its University College Venlo has been announced to open in September 2014. Wikipedia.
Eijssen L.M.,Maastricht University
Nucleic acids research | Year: 2013
Quality control (QC) is crucial for any scientific method producing data. Applying adequate QC introduces new challenges in the genomics field where large amounts of data are produced with complex technologies. For DNA microarrays, specific algorithms for QC and pre-processing including normalization have been developed by the scientific community, especially for expression chips of the Affymetrix platform. Many of these have been implemented in the statistical scripting language R and are available from the Bioconductor repository. However, application is hampered by lack of integrative tools that can be used by users of any experience level. To fill this gap, we developed a freely available tool for QC and pre-processing of Affymetrix gene expression results, extending, integrating and harmonizing functionality of Bioconductor packages. The tool can be easily accessed through a wizard-like web portal at http://www.arrayanalysis.org or downloaded for local use in R. The portal provides extensive documentation, including user guides, interpretation help with real output illustrations and detailed technical documentation. It assists newcomers to the field in performing state-of-the-art QC and pre-processing while offering data analysts an integral open-source package. Providing the scientific community with this easily accessible tool will allow improving data quality and reuse and adoption of standards. Source
Maastricht University and Academisch Ziekenhuis Maastricht | Date: 2014-07-16
The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
Maastricht University and University of Vermont | Date: 2013-11-12
The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like.
Maastricht University and Academisch Ziekenhuis Maastricht | Date: 2013-09-12
The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled-1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.
Maastricht University | Date: 2014-05-05
The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.